-
14141por Han, Qunying, Fan, Xiude, Wang, Xiaoyun, Wang, Ye, Deng, Huan, Zhang, Xiaoge, Zhang, Kun, Li, Na, Liu, Zhengwen“…BACKGROUND: Patients with hepatitis C virus (HCV) genotype 3 infection remain a difficult-to-cure population. …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14142“…The main causes for this condition are chronic alcohol abuse, nonalcoholic steatohepatitis, and infection due to hepatitis C virus. Currently, there is more and more information available about the molecular as well as cellular mechanisms, which play a role in the advancement of liver fibrosis. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14143por Wang, Ningjian, Wan, Heng, Wang, Yuying, Chen, Chi, Chen, Yi, Xia, Fangzhen, Han, Bing, Li, Qin, Zhang, Wen, Jensen, Michael, Lu, Yingli“…Subjects with a history of excessive consumption (male ≥20 g/d, female ≥10 g/d) of pure alcohol, viral hepatitis (including hepatitis B and hepatitis C virus), using medications associated with secondary NAFLD were excluded. …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14144por Shiha, Gamal, Esmat, Gamal, Hassany, Mohamed, Soliman, Reham, Elbasiony, Mohamed, Fouad, Rabab, Elsharkawy, Aisha, Hammad, Radi, Abdel-Razek, Wael, Zakareya, Talaat, Kersey, Kathryn, Massetto, Benedetta, Osinusi, Anu, Lu, Sophia, Brainard, Diana M, McHutchison, John G, Waked, Imam, Doss, Wahid“…OBJECTIVE: We evaluated the efficacy and safety of ledipasvir/sofosbuvir alone and with ribavirin for 8 and 12 weeks in Egyptian patients with and without cirrhosis, who were infected with hepatitis C virus (HCV) genotype 4, including those who had failed previous treatment with sofosbuvir regimens. …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14145por Chen, Chun-Wei, Cheng, Jur-Shan, Chen, Tai-Di, Le, Puo-Hsien, Ku, Hsin-Ping, Chang, Ming-Ling“…BACKGROUND: Hepatitis C virus (HCV) infection causes many extrahepatic malignancies; whether it increases gastric cancer risk and the risk reverses after anti-HCV therapy remain elusive. …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14146por Suzuki, Naoki, Mori-Yoshimura, Madoka, Yamashita, Satoshi, Nakano, Satoshi, Murata, Ken-ya, Mori, Megumi, Inamori, Yukie, Matsui, Naoko, Kimura, En, Kusaka, Hirofumi, Kondo, Tomoyoshi, Ito, Hidefumi, Higuchi, Itsuro, Hashiguchi, Akihiro, Nodera, Hiroyuki, Kaji, Ryuji, Tateyama, Maki, Izumi, Rumiko, Ono, Hiroya, Kato, Masaaki, Warita, Hitoshi, Takahashi, Toshiaki, Nishino, Ichizo, Aoki, Masashi“…Eight patients were positive for anti-hepatitis C virus antibody; three of them were administered interferon before sIBM onset. …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14147por Mera, Jorge, Joshi, Kartik, Thornton, Karla, Box, Terry, Scott, John, Sedillo, Miranda, Deming, Paulina, David, Crystal, Essex, Whitney, Manch, Richard, Kohli, Anita“…BACKGROUND: Treatment for chronic hepatitis C virus (HCV) has rapidly evolved to simple, well-tolerated, all-oral regimens of direct-acting antivirals (DAAs). …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14148por Paolucci, Stefania, Novazzi, Federica, Piralla, Antonio, Maserati, Renato, Gulminetti, Roberto, Novati, Stefano, Barbarini, Giorgio, Sacchi, Paolo, Fratini, Alice, Bellotti, Laura, Baldanti, Fausto“…BACKGROUND: New hepatitis C virus (HCV) therapies have improved efficacy, allowed pangenotypic applications, increased barriers to drug resistance and shortened therapy duration. …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14149“…CONCLUSIONS: Spending associated with essential medicines grew substantially from 2011 to 2015, driven largely by the increased use of two expensive novel drugs used in treating hepatitis C. Approximately 22% of increased total spending during this period can be attributed to increases in per unit cost of existing drugs. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14150por Frempong, Margaret T., Ntiamoah, Paul, Annani-Akollor, Max Efui, Owiredu, William K. B. A., Addai-Mensah, Otchere, Owiredu, Eddie-Williams, Adu-Gyasi, Denis, Agyapong, Evans Owusu, Sallah, Lorraine“…BACKGROUND: Hepatitis B (HBV) or hepatitis C (HCV) virus co-infections in HIV are alarming during pregnancy due to the risk of vertical transmission and the eventual adverse effects on neonates. …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14151por Chehl, Navdeep, Maheshwari, Anurag, Yoo, Hwan, Cook, Colleen, Zhang, Talan, Brown, Sara, Thuluvath, Paul J.“…The real-world cure rates for hepatitis C (HCV) with direct-acting antivirals (DAAs) based on intention-to-treat (ITT) analysis may be lower than reported in the literature because of non-compliance. …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14152por Allen, Niamh, Faherty, Collette, Davies, Andre, Lyons, Anne, Scarry, Margarent, Bohan Keane, Mary, Boyle, Nicola, O’Connell, Sarah, McCarthy, Eithne, Keady, Deirbhile, Bergin, Colm, Lee, John, Fleming, Catherine, Gallagher, David, Tuite, Helen“…OBJECTIVE: Recent treatment developments for HIV, hepatitis C virus (HCV) and hepatitis B virus (HBV) have greatly improved prognoses. …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14153“…Using a large U.S. clinical laboratory database from 10/1/2017-9/30/2018, adults negative for hepatitis B and hepatitis C and after excluding for alcoholic liver disease and pregnancy were evaluated for prevalence of F3 and F4 fibrosis using a systematic algorithm of five fibrosis-4 (FIB-4) criteria: Criteria 1 (≥F3: >2.67), Criteria 2 (2.67<F3≤4.12 and F4>4.12), Criteria 3 (2.67<F3≤3.15, F4>3.15), Criteria 4 (3.25<F3≤3.5, F4>3.5), Criteria 5 (3.25<F3≤4.12, F4>4.12). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14154por Kassim, Saba, Othman, Badr, AlQahtani, Sakher, Kawthar, Alemad Mustafa, McPherson, Sterling M., Greenberg, Barbara L.“…The majority felt it was important for a dentist to screen for cardiovascular disease (98.6%), hypertension (97.9%), diabetes (97.9%), human immunodeficiency virus (HIV) (97.9%), and hepatitis C virus (98.6%). Respondents were willing to refer a patient to a physician (97.9%); send samples to an outside laboratory (96.1%); conduct screening that yields immediate results (96.2%); and discuss results immediately with the patient (93.7%). …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14155por Covés-Datson, Evelyn M., Dyall, Julie, DeWald, Lisa Evans, King, Steven R., Dube, Derek, Legendre, Maureen, Nelson, Elizabeth, Drews, Kelly C., Gross, Robin, Gerhardt, Dawn M., Torzewski, Lisa, Postnikova, Elena, Liang, Janie Y., Ban, Bhupal, Shetty, Jagathpala, Hensley, Lisa E., Jahrling, Peter B., Olinger, Gene G., White, Judith M., Markovitz, David M.“…H84T shows activity against viruses containing high-mannose N-glycans, including influenza A and B, HIV-1 and -2, and hepatitis C virus. Since ebolavirus surface glycoproteins also contain many high-mannose N-glycans, we assessed whether H84T could inhibit ebolavirus replication. …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14156por Vranjkovic, Agatha, Deonarine, Felicia, Kaka, Shaima, Angel, Jonathan B., Cooper, Curtis L., Crawley, Angela M.“…Chronic hepatitis C virus (HCV) infection disrupts immune functions, including that of cytotoxic CD8(+) T-cells which are important mediators of immune response. …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14157por Zhang, Mingyuan, Wu, Ruihong, Xu, Hongqin, Uhanova, Julia, Gish, Robert, Wen, Xiaoyu, Jin, Qinglong, Gerald, Minuk Y, Nguyen, M H, Gao, Yanhang, Niu, J“…Hepatitis B (HBV) (n=13 543 137, 80.00%) and hepatitis C (HCV) (n=1 844 882, 10.90%) accounted for >90% of the cases. …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14158“…AIM: Hepatitis C virus (HCV) is the leading cause of hepatocellular carcinoma (HCC) in the United States. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14159por Poudyal, Deepak, Yang, Jun, Chen, Qian, Goswami, Suranjana, Adelsberger, Joseph W., Das, Sudipto, Herman, Andrew, Hornung, Ronald L., Andresson, Thorkell, Imamichi, Tomozumi“…IL-27 is known as an antiviral cytokine that inhibits HIV, hepatitis C virus, and other viruses. We have previously demonstrated that, IL-27 posttreatment after HIV-infection inhibits viral replication in primary CD4(+) T cells. …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14160“…Such groups include: Coronaviridae (severe acute respiratory syndrome and Middle East respiratory syndrome-associated coronaviruses), Picornaviridae (Hepatitis A virus), Flaviviridae (Yellow fever, West Nile, Hepatitis C, Dengue, and Zika viruses), Togaviridae (Rubella and Chikungunya virus), Bornaviridae (Borna-disease virus), Filoviridae (Ebola and Marburg viruses), Paramyxoviridae (Measles, Nipah, and Hendra viruses), Rhabdoviridae (Lyssaviruses), Arenaviridae (Lassa virus), Bunyaviridae (Hanta- and Crimean-Congo hemorrhagic fever viruses), and Orthomyxoviridae (Influenza A viruses). …”
Enlace del recurso
Enlace del recurso
Online Artículo Texto